Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 124 Show results per page	View Search Criteria \| Help With Results

	Title				Phase				Protocol IDs

	Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis				Phase III, Phase II				20050113 NCT00243685
	Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas				Phase III, Phase II				WIRB 20060042 NCT00443196
	Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer				Phase III				DUMC03 DUKE UNIVERSITY MEDICAL CENTER, CLINICAL STUDY PROTOCOL, NCT00090610
	Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer				Phase III				CEPO906A2303 NCT00262990
	OVATURE (OVArian TUmor REsponse) Study: A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer				Phase III				NV06-0039 NCT00382811
	A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma (OCEANS)				Phase III				AVF4095g NCT00434642
	Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients with Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer				Phase III				GOG-0213 GOG-0213, NCT00565851
	Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer				Phase III				KTN32313R NCT00477282
	Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Allogeneic Transplantation				Phase II, Phase I				FHCRC-1803.00 5606, NCT00068718
	Ixabepilone and Liposomal Doxorubicin in Treating Women With Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer or Metastatic Breast Cancer				Phase II, Phase I				AECM-0504007857 NCI-7229, 7229, NCT00182767


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute